Anti‐(+)‐Methamphetamine Monoclonal Antibody Antagonists Designed to Prevent the Progression of Human Diseases of Addiction | Zendy

Gentry W B | Zendy; RüediBettschen D | Zendy; Owens S M | Zendy

Premium

Anti‐(+)‐Methamphetamine Monoclonal Antibody Antagonists Designed to Prevent the Progression of Human Diseases of Addiction

Author(s) -

Gentry W B,

RüediBettschen D,

Owens S M

Publication year - 2010

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2010.155

Subject(s) - methamphetamine , meth , addiction , clinical pharmacology , abstinence , monoclonal antibody , medicine , pharmacology , vulnerability (computing) , psychiatry , immunology , antibody , computer security , chemistry , monomer , organic chemistry , acrylate , computer science , polymer

Anti‐(+)‐methamphetamine monoclonal antibodies (mAbs) have the potential to reduce the devastating behavioral and societal effects of the worldwide epidemic of (+)‐methamphetamine (METH) addiction and transform the treatment paradigm for diseases of addiction. These novel, protein‐based medications could play a vital role in helping patients to achieve sustainable abstinence from METH abuse by serving as an in vivo , around‐the‐clock sentry against a patient's vulnerability to relapse. Clinical Pharmacology & Therapeutics (2010) 88 3, 390–393. doi: 10.1038/clpt.2010.155

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research